Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Managing treatment toxicities when developing novel agents for MPNs

Naveen Pemmaraju • 11 Apr 2022
AACR 2022
Myeloproliferative Neoplasms

Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, emphasizes having a patient-centered focus when developing novel therapies due to the new toxicities that novel agents bring. It is essential to consider the toxicity of the novel agent itself, the overlapping toxicities which arise in combination therapy, and the long-term and off-target effects of the novel agents. Dr Pemmaraju highlights the utility of the ‘myeloproliferative neoplasms (MPNs) symptom burden questionnaire’ when developing novel agents. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals